XJPX4598
Market cap22mUSD
Jan 07, Last price
540.00JPY
1D
-2.88%
1Q
-0.74%
IPO
-88.63%
Name
Delta-Fly Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-51.96%
Revenues
0k
Net income
-1.43b
L+7.57%
CFO
-1.28b
L-1.80%
Profile
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 300,000 0.00% | ||||
Cost of revenue | 1,404,975 | 1,317,441 | 1,261,462 | ||
Unusual Expense (Income) | |||||
NOPBT | (1,404,975) | (1,317,441) | (961,462) | ||
NOPBT Margin | |||||
Operating Taxes | 2,502 | 3,028 | 3,237 | ||
Tax Rate | |||||
NOPAT | (1,407,477) | (1,320,469) | (964,699) | ||
Net income | (1,429,393) 7.57% | (1,328,788) 37.37% | (967,302) 12.14% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,849,479 | 878,644 | 119,857 | ||
BB yield | -30.73% | -15.05% | -1.73% | ||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 2,000 | ||||
Net debt | (1,417,062) | (845,341) | (1,271,492) | ||
| Cash flow | |||||
Cash from operating activities | (1,279,615) | (1,303,049) | (940,399) | ||
CAPEX | (1,132) | (321) | |||
Cash from investing activities | 207 | (326) | |||
Cash from financing activities | 1,853,195 | 882,617 | 119,857 | ||
FCF | (1,407,098) | (1,319,157) | (963,038) | ||
| Balance | |||||
Cash | 1,417,062 | 844,341 | 1,268,492 | ||
Long term investments | 1,000 | 3,000 | |||
Excess cash | 1,417,062 | 845,341 | 1,256,492 | ||
Stockholders' equity | (3,478,940) | (2,983,611) | (2,099,616) | ||
Invested Capital | 4,711,597 | 3,774,809 | 3,312,892 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 7,191 | 5,666 | 5,417 | ||
Price | 837.00 -18.74% | 1,030.00 -19.53% | 1,280.00 -7.58% | ||
Market cap | 6,018,838 3.13% | 5,836,254 -15.82% | 6,933,341 8.73% | ||
EV | 4,601,776 | 4,990,913 | 5,662,849 | ||
EBITDA | (1,403,463) | (1,315,809) | (959,790) | ||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||